Headlines about Immune Pharmaceuticals (NASDAQ:IMNP) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.476175915692 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
NASDAQ:IMNP traded down $0.01 during mid-day trading on Thursday, hitting $0.23. 2,255,888 shares of the stock were exchanged, compared to its average volume of 1,116,044. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.31 and a quick ratio of 0.31. Immune Pharmaceuticals has a fifty-two week low of $0.21 and a fifty-two week high of $3.43.
Immune Pharmaceuticals (NASDAQ:IMNP) last released its quarterly earnings results on Tuesday, May 15th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.